Last $713.96 MXN
Change Today 0.00 / 0.00%
Volume 0.0
TEVAN On Other Exchanges
Symbol
Exchange
New York
Tel Aviv
OTC US
Mexico
Frankfurt
As of 4:09 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Basel Street

Petach Tikva, 49131

Israel

Phone: 972 3 926 7267

Fax: 972 3 923 4050

od cells implicated in a number of allergic diseases. Fluticasone & salmeterol MDPI is a new formulation of this combination using the company’s multi-dose powder inhaler device, with an enhanced lung delivery that is designed to allow lower doses to achieve the same clinical outcomes as Advair Diskus. Fluticasone MDPI is a new formulation of this combination using the company’s multi-dose powder inhaler device. Phase II trials were completed in 2013, and initiation of the Phase III program is planned for 2014. Teva-MicroDose RSV is a transformational inhaled delivery technology being developed for the treatment of respiratory syncytial virus (RSV) infection. Phase II clinical trials were initiated in 2013. Fluticasone & salmeterol HFA MDI is designed to be comparable to Advair/Seretide HFA, delivered in a well established press-and-breath device. Long-Acting Muscarinic Antagonist (LAMA) BAI is an oral aerosol LAMA in development for the treatment of COPD, delivered using the company’s advanced breath-actuated inhaler. The company completed a phase I study in 2013 and plans to enter Phase II as well as initiate a Japanese bridging study in 2014. Oncology Balugrastim (albumin fused G-CSF) is a long-acting G-CSF using albumin-fusion technology initially developed by Human Genome Sciences to prolong plasma half-life. Balugrastim is designed to provide clinical efficacy and safety profiles comparable to Neulasta. The company submitted balugrastim for registration in Europe in April 2013. Custirsen/TV-1011 (OGX-011) is an antisense drug. In 2009, Teva and OncoGenex entered into a global license and collaboration agreement to develop and commercialize custirsen/TV-1011 (OGX-011). Custirsen was developed by Isis Pharmaceuticals Inc. and licensed to OncoGenex, and is designed to inhibit the production of clusterin, a protein associated with cancer treatment resistance. In 2012, enrollment was completed in a large Phase III randomized trial of custirsen in combination with docetaxel and prednisone in the initial chemotherapy treatment of patients with castrate-resistant prostate cancer. Custirsen is protected by patents expiring in 2020 in Europe and in 2021 in the United States. Women’s Health Ovaleap (XM17, follitropin alfa) is a biosimilar product to Gonal-f for the treatment of female infertility. The product was approved for marketing in Europe in September 2013. Milprosa (progesterone vaginal ring) is a silicone-based, flexible ring designed to be dosed weekly for luteal support for in vitro fertilization. Clinical studies indicated that Milprosa is not inferior to the approved progesterone gel and is safe and well-tolerated, with a profile consistent with the known profile of progesterone. Milprosa is protected by patents expiring in 2030 in the United States, with patents pending in Europe. LeCette is a 28-day oral contraceptive with 21-day regimen of desogestrel and ethinyl estradiol followed by a 7-day regimen of ethinyl estradiol alone. Phase III clinical development was completed in 2013 and an NDA was filed during 2013. LeCette is protected by patents expiring in 2022 in the United States. Cardiovascular Revascor (mesynchymal precursor cells) consists of human stem cells, the immature cells that give rise to different types of mature cells that make up the organs and tissues of the human body. In 2010, the company entered into a strategic alliance with Mesoblast Ltd. to develop and commercialize Mesoblast’s mesenchymal precursor cell therapeutics for hematopoietic stem cell transplantation in cancer patients, certain central nervous system disorders, as well as certain cardiovascular conditions, including congestive heart failure and acute myocardial infarction. Acquisitions In July 2013, the company acquired MicroDose Therapeutx, Inc. (MicroDose), a pharmaceutical and drug delivery company focused on inhalation technologies and products for lung diseases and infections. Agreements In 2012, the company entered into a collaborative development and exclusive worldwide license agreement with Xenon Pharmaceuticals Inc. (Xenon) for its compound XEN402. XEN402 targets so

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVAN:MM $713.96 MXN 0.00

TEVAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.93 USD -0.11
AbbVie Inc $53.74 USD +0.56
Actavis plc $214.94 USD -2.51
Baxter International Inc $76.47 USD -0.18
Eli Lilly & Co $63.39 USD -0.39
View Industry Companies
 

Industry Analysis

TEVAN

Industry Average

Valuation TEVAN Industry Range
Price/Earnings 33.4x
Price/Sales 2.3x
Price/Book 2.0x
Price/Cash Flow 37.5x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.